Seretide
GSK double complaint ruled out by PMCPA
January 16, 2015Medical Communications, Sales and Marketing ABPI, COPD, GSK, PMCPA, Relvar, Seretide
Complaints questioning the promotion of two of GlaxoSmithKline’s chronic obstructive pulmonary disease (COPD) drugs have been ruled out by a …
GSK sees profit fall
May 1, 2014Sales and Marketing Advair, China, GSK, Novartis, Q1, Seretide, Witty
GlaxoSmithKline has seen revenue and profit plummet in the first quarter of 2014. The UK-based company saw turnover fall 13% …
GSK sales up – impact of China allegations to follow
July 24, 2013Sales and Marketing GSK, Q2, Seretide, Seroxat, Witty, bribery, transparency
GlaxoSmithKline has reported a modest rise in sales but the fallout from China’s bribery probe dominates the firm’s release of …
Almirall’s COPD drug launched in Europe
September 20, 2012Sales and Marketing Advair, Almirall, Eklira, Genuair, Seretide, Spiriva
Almirall has launched COPD treatment Eklira in Denmark following approval from the European Commission. Phase III trials demonstrated that Eklira …
GSK falters in Q2 as austerity measures bite
July 25, 2012Sales and Marketing Benylsta, GSK, Q2, Seretide, Witty
GlaxoSmithKline posted a loss in its second quarter results, as pressure in mature markets continues to affect the firm. Pharmaceutical …
GSK posts strong underlying sales growth
February 8, 2012Research and Development, Sales and Marketing Avodart, GSK, R&D, Seretide, Witty, rotarix
GlaxoSmithKline has posted strong underlying growth for 2011, but warns of a tough year ahead. The UK firm saw 4% …
Underwhelming results for GSK’s Relovair
January 10, 2012Research and Development, Sales and Marketing Advair, COPD, GSK, Relovair, Seretide, asthma
GlaxoSmithKline says it is on track to file its respiratory drug Relovair in Europe and the US despite mixed results …
GSK cleared of unethical practices by PMCPA
October 22, 2010Medical Communications ABPI, ABPI Code of Practice, Avamys, GSK, GlaxoSmithKline, PMCPA, Rupafin, Seretide
GlaxoSmithKline has been found guilty of two transgressions of the ABPI Code of Practice in a case centring on the …
German patent setback for GlaxoSmithKline’s Seretide
May 21, 2010Sales and Marketing GSK, Germany, Seretide
A Munich court has ruled GlaxoSmithKline’s combination patent for its asthma and COPD treatment Seretide is not valid. The Federal …
GSK’s Relovair moves into phase III
March 19, 2010Research and Development GlaxoSmithKline, Relovair, Seretide, Theravance, respiratory
GlaxoSmithKline has started phase III asthma trials of Relovair, the respiratory treatment it is developing with San Francisco biopharma firm …
GSK begins phase III COPD trials
October 28, 2009Research and Development, Sales and Marketing COPD, GSK, GlaxoSmithKline, Seretide, Theravance, resp, respiratory
GlaxoSmithKline and San Francisco biopharma firm Theravance have begun a phase III trial to develop a new treatment for chronic …
